Reddy博士的实验室报告Q3利润增长2%, 收入增长16%, Dr. Reddy's Labs reports Q3 profit up 2%, revenue jumps 16%, but shares drop 7% amid analyst concerns.

Dr. Reddy's Laboratories 报告称，截至 2024 年 12 月的第三季度，净利润增长 2% 至 141.3 亿卢比，收入增长 16% 至 835.9 亿卢比。 Dr. Reddy's Laboratories reported a 2% rise in net profit to ₹1,413 crore and a 16% increase in revenue to ₹8,359 crore for the third quarter ended December 2024. 增长的驱动因素是最近获得的尼古丁替代疗法(NRT)业务、新产品推出以及效率的提高。 Growth was driven by the recently acquired Nicotine Replacement Therapy (NRT) business, new product launches, and improved efficiencies. 尽管取得了财政收益,但由于分析师的评分不一,对竞争加剧和核心盈利问题感到关切,公司股份下跌了约7%。 Despite the financial gains, the company’s shares fell by around 7% due to mixed analyst ratings and concerns over increased competition and core profitability issues. 欧洲收入猛增143%,而北美收入略有上升1%。 European revenues surged 143%, while North American revenues rose modestly by 1%. 该公司还与Gilead Science公司签订了艾滋病毒治疗药物许可协议。 The company also entered a licensing agreement with Gilead Sciences for an HIV treatment drug.